Skip to main content

Table 5 Patient outcomes according to the value of the initial and maximal trough concentration (Cmin)

From: Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days

Outcomes

No. of patients with initial Cmin

No. of patients with maximal Cmin

< 20 μg/mL

≥20 μg/mL

P-value

< 20 μg/mL

≥20 μg/mL

P-value

Early clinical response (n = 76)

23/37 (62.2%)

31/39 (79.5%)

0.096

Clinical success at the end of therapy (n = 76)

25/37 (67.6%)

30/39 (76.9%)

0.362

22/33 (66.7%)

33/43 (76.7%)

0.330

Microbiological success (n = 68)

22/33 (66.7%)

25/35 (71.4%)

0.671

20/31 (64.5%)

27/37 (73.0%)

0.452

28 days mortality (n = 76)

5/37 (13.5%)

2/39 (5.1%)

0.256

5/33 (15.2%)

2/43 (4.7%)

0.229

  1. Eight patients in whom culture results after the start of therapy were not obtained were excluded from the microbiological success analysis